# The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

> **NCT00405067** · PHASE2 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** BMS-201038 (AEGR-733)
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT00405067
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405067, "The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00405067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*